25 Nov FSHD NEWS: New drug targets for a form of muscular dystrophy

Article originally appeared on sciencedaily.com, November 7, 2017. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle...

Read More

25 Nov FSHD NEWS: Resolaris Improved Muscle Strength of Nearly Two-thirds of FSHD Patients, Phase 1/2 Trial Shows

Article originally appeared on musculardystrophynews.com, October 10, 2017. Resolaris (ATYR1940) improved the muscle strength of nearly two-thirds of adolescents and young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD), according to final results of a Phase 1/2 clinical trial. The therapy’s maker, aTyr Pharma, presented the findings at the 22nd International Annual Congress of the World Muscle Society...

Read More

17 Jun June 20th is World FSHD Day

    Post by Chris Carrino June 20th is World FSHD Day. A day of awareness for FSHD, to show we are united for a cure. However, for those of us affected by this disease, June 20th is simply known as  - Tuesday. There isn’t a moment of every day that...

Read More

19 Sep PRESS RELEASE: The Chris Carrino Foundation for FSHD Extends Funding of Genetic Research Project

September 19, 2011 Massapequa Park, New York The Chris Carrino Foundation for FSHD announced the extension of a scientific research project directed towards understanding the genetic basis of variable severity in FSHD (Facioscapulohumeral Muscular Dystrophy). The study, entitled, "Uncovering the Genetic Basis of Variable Severity in FSHD"...

Read More